PRFX

PainReform Ltd. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website ainreform.com
Employees(FY) 6
ISIN IL0011651580

Performance

+81.51%

-5.36%

+76.08%

+79.9%

-67.88%

YTD

-64.43%

Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. It is currently conducting Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Advanced Technical Analysis

Technical Analysis of PRFX 2024-12-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90, indicating robust upward momentum, while the Oscillators Score of 43 suggests a neutral stance that may warrant caution. Overall, the Technical Score of 66 reinforces a generally positive outlook, though investors should remain aware of potential fluctuations indica...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of PRFX

Stock Rank

Recent News & Updates

2024-11-19 19:30
PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial(Globenewswire)
2024-11-07 04:00
PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement(Globenewswire)
2024-10-24 21:25
PainReform cut to Hold at Maxim amid changed market dynamics(Yahoo Finance)
2024-09-10 20:30
PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110(Globenewswire)
2024-09-09 21:46
PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds(Globenewswire)
2024-09-09 00:14
Upcoming Stock Splits This Week (September 9 to September 13) Stay Invested(Yahoo Finance)
2024-08-20 20:30
PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy Procedures(Globenewswire)
2024-08-19 20:30
PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study(Globenewswire)
2024-08-14 20:00
PainReform Provides Business Update for the Second Quarter of 2024(Globenewswire)
2024-08-11 21:00
PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic Effects(Globenewswire)
2024-08-06 22:00
PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses(Globenewswire)
2024-08-04 21:00
PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110(Globenewswire)
2024-07-31 20:30
PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature(Globenewswire)
2024-07-23 20:30
PainReform Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and Testing(Globenewswire)
2024-06-25 20:00
PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110(Globenewswire)
2024-06-13 19:30
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday(Investorplace)
2024-05-31 04:15
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification(Globenewswire)
2024-05-15 10:54
PRFX Stock Earnings: PainReform Misses EPS for Q1 2024(Investorplace)
2024-05-15 04:05
PainReform Provides Business Update for the First Quarter of 2024(Globenewswire)
2024-05-07 20:30
PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com(Globenewswire)
2024-04-18 02:19
PainReform Announces Closing of $4 Million Public Offering(Globenewswire)
2024-04-15 20:00
PainReform Announces Pricing of $4 Million Public Offering(Globenewswire)
2024-04-08 22:30
EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions(Yahoo Finance)
2024-04-08 21:00
PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions(Globenewswire)
2024-04-01 22:00
EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug(Yahoo Finance)
2024-04-01 20:30
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy(Globenewswire)
2024-02-29 19:00
PainReform Provides Year-End Business Update(Globenewswire)
2024-01-21 19:30
PainReform to Present at the Microcap Conference in Atlantic City(Globenewswire)
2024-01-02 19:30
PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief(Globenewswire)
2023-12-26 05:00
PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds(Globenewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.